ARCHIVES

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities: NIH seeks “visionary thinkers” for awards of $2.5 million over five years. NCI RFA available.

January 23, 2004

ASCO To Open Abstracts To Everyone Prior To Annual Meeting.

November 16, 2007

In Brief: Selection Of NCI Director Extended By Month; Fisher Named NSABP Scientific Director

March 17, 1995

Goodfellow To Lead Gynecologic Oncology Research Team At Ohio State University

January 11, 2013

Columbus CCP Forms New Entity to Administer CCOP

July 20, 1990

Conference On Delayed Consequences Of Cancer Therapy Scheduled Jan. 9-11

January 3, 1975